{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:24:20Z","timestamp":1717460660028},"reference-count":64,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"DOI":"10.7759\/cureus.61557","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T07:13:46Z","timestamp":1717398826000},"source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulation in Atrial Fibrillation Associated With Cardiac Amyloidosis: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Tejbir S","family":"Monga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mfonido","family":"Ekong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay\u00e9","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulasi Geethika","family":"Bommana Boyena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneela Satya","family":"Ravanam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Bengisu","family":"Mavus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A P","family":"Lakshmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanwaraj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramya Reshma","family":"Vegesna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13443","article-title":"Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature","volume":"8","author":"Adam RD","year":"2021","unstructured":"Adam RD, Coriu D, Jercan A, B\u0103deli\u0163\u0103 S, Popescu BA, Damy T, Jurcu\u0163 R. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Fail. 2021, 8:2380-96. 10.1002\/ehf2.13443","journal-title":"ESC Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez E","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al.. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015, 36:2585-94. 10.1093\/eurheartj\/ehv338","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2024.03.008","article-title":"Atrial fibrillation in the setting of cardiac amyloidosis - a review of the literature","author":"Bazoukis G","year":"2024","unstructured":"Bazoukis G, Saplaouras A, Efthymiou P, et al.. Atrial fibrillation in the setting of cardiac amyloidosis - a review of the literature. J Cardiol. 2024, 10.1016\/j.jjcc.2024.03.008","journal-title":"J Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10080337","article-title":"Arrhythmias in patients with cardiac amyloidosis: a comprehensive review on clinical management and devices","volume":"10","author":"Briasoulis A","year":"2023","unstructured":"Briasoulis A, Kourek C, Papamichail A, et al.. Arrhythmias in patients with cardiac amyloidosis: a comprehensive review on clinical management and devices. J Cardiovasc Dev Dis. 2023, 10:337. 10.3390\/jcdd10080337","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac\u00a0amyloidosis","volume":"6","author":"Giancaterino S","year":"2020","unstructured":"Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac\u00a0amyloidosis. JACC Clin Electrophysiol. 2020, 6:351-61. 10.1016\/j.jacep.2020.01.004","journal-title":"JACC Clin Electrophysiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2005.1.1.92","article-title":"Embolic infarction associated with cardiac amyloidosis","volume":"1","author":"Cho KH","year":"2005","unstructured":"Cho KH, Cho YM, Kim JS. Embolic infarction associated with cardiac amyloidosis. J Clin Neurol. 2005, 1:92-6. 10.3988\/jcn.2005.1.1.92","journal-title":"J Clin Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches S","year":"2022","unstructured":"Vilches S, Fontana M, Gonzalez-Lopez E, et al.. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022, 24:1387-96. 10.1002\/ejhf.2566","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101571","article-title":"Epidemiology, mechanisms, and management of atrial fibrillation in cardiac amyloidosis","volume":"48","author":"Bukhari S","year":"2023","unstructured":"Bukhari S, Oliveros E, Parekh H, Farmakis D. Epidemiology, mechanisms, and management of atrial fibrillation in cardiac amyloidosis. Curr Probl Cardiol. 2023, 48:101571. 10.1016\/j.cpcardiol.2022.101571","journal-title":"Curr Probl Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1798922","article-title":"Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation","volume":"28","author":"Cappelli F","year":"2021","unstructured":"Cappelli F, Tini G, Russo D, et al.. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid. 2021, 28:12-8. 10.1080\/13506129.2020.1798922","journal-title":"Amyloid"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.08.008","article-title":"Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis: a review","volume":"29","author":"Bukhari S","year":"2023","unstructured":"Bukhari S, Khan SZ, Bashir Z. Atrial fibrillation, thromboembolic risk, and anticoagulation in cardiac amyloidosis: a review. J Card Fail. 2023, 29:76-86. 10.1016\/j.cardfail.2022.08.008","journal-title":"J Card Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072651","article-title":"Atrial remodeling is directly related to end-diastolic left ventricular pressure in a mouse model of ventricular pressure overload","volume":"8","author":"De Jong AM","year":"2013","unstructured":"De Jong AM, Van Gelder IC, Vreeswijk-Baudoin I, Cannon MV, Van Gilst WH, Maass AH. Atrial remodeling is directly related to end-diastolic left ventricular pressure in a mouse model of ventricular pressure overload. PLoS ONE. 2013, 8:e72651. 10.1371\/journal.pone.0072651","journal-title":"PLoS ONE"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: an update on diagnosis and treatment","volume":"84","author":"Donnelly JP","year":"2017","unstructured":"Donnelly JP, Hanna M. Cardiac amyloidosis: an update on diagnosis and treatment. Cleve Clin J Med. 2017, 84:12-26. 10.3949\/ccjm.84.s3.02","journal-title":"Cleve Clin J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.749523","article-title":"Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination","volume":"8","author":"Porcari A","year":"2021","unstructured":"Porcari A, Bussani R, Merlo M, Varr\u00e0 GG, Pagura L, Rozze D, Sinagra G. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination. Front Cardiovasc Med. 2021, 8:749523. 10.3389\/fcvm.2021.749523","journal-title":"Front Cardiovasc Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26154611","article-title":"The ultrastructure of tissue damage by amyloid fibrils","volume":"26","author":"Koike H","year":"2021","unstructured":"Koike H, Katsuno M. The ultrastructure of tissue damage by amyloid fibrils. Molecules. 2021, 26:4611. 10.3390\/molecules26154611","journal-title":"Molecules"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-020-00210-7","article-title":"Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies","volume":"9","author":"Koike H","year":"2020","unstructured":"Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther. 2020, 9:317-33. 10.1007\/s40120-020-00210-7","journal-title":"Neurol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Hartnett J","year":"2021","unstructured":"Hartnett J, Jaber W, Maurer M, et al.. Electrophysiological manifestations of cardiac amyloidosis: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2021, 3:506-15. 10.1016\/j.jaccao.2021.07.010","journal-title":"JACC CardioOncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072581","article-title":"Arrhythmic manifestations of cardiac amyloidosis: challenges in risk stratification and clinical management","volume":"12","author":"Laptseva N","year":"2023","unstructured":"Laptseva N, Rossi VA, Sudano I, Schwotzer R, Ruschitzka F, Flammer AJ, Duru F. Arrhythmic manifestations of cardiac amyloidosis: challenges in risk stratification and clinical management. J Clin Med. 2023, 12:2581. 10.3390\/jcm12072581","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82554-0","article-title":"Morpho-functional changes of cardiac telocytes in isolated atrial amyloidosis in patients with atrial fibrillation","volume":"11","author":"Sukhacheva TV","year":"2021","unstructured":"Sukhacheva TV, Nizyaeva NV, Samsonova MV, et al.. Morpho-functional changes of cardiac telocytes in isolated atrial amyloidosis in patients with atrial fibrillation. Sci Rep. 2021, 11:3563. 10.1038\/s41598-021-82554-0","journal-title":"Sci Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000034511.06350.df","article-title":"Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation","volume":"106","author":"R\u00f6cken C","year":"2002","unstructured":"R\u00f6cken C, Peters B, Juenemann G, et al.. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002, 106:2091-7. 10.1161\/01.cir.0000034511.06350.df","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan E","year":"2020","unstructured":"Donnellan E, Wazni OM, Saliba WI, et al.. Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. Am J Cardiol. 2020, 128:140-6. 10.1016\/j.amjcard.2020.05.021","journal-title":"Am J Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr BC","year":"2014","unstructured":"Varr BC, Zarafshar S, Coakley T, et al.. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014, 11:158-62. 10.1016\/j.hrthm.2013.10.026","journal-title":"Heart Rhythm"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9842","article-title":"Association of arrhythmias in cardiac amyloidosis and cardiac sarcoidosis","volume":"12","author":"Ashraf I","year":"2020","unstructured":"Ashraf I, Peck MM, Maram R, Mohamed A, Ochoa Crespo D, Kaur G, Malik BH. Association of arrhythmias in cardiac amyloidosis and cardiac sarcoidosis. Cureus. 2020, 12:e9842. 10.7759\/cureus.9842","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"Al (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk RH","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. Al (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016, 68:1323-41. 10.1016\/j.jacc.2016.06.053","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg FL","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019, 73:2872-91. 10.1016\/j.jacc.2019.04.003","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng D","year":"2007","unstructured":"Feng D, Edwards WD, Oh JK, et al.. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007, 116:2420-6. 10.1161\/CIRCULATIONAHA.107.697763","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.03.005","article-title":"Serum free light chain difference and \u03b22 microglobulin levels are risk factors for thromboembolic events in patients with AL\u00a0amyloidosis","volume":"18","author":"Park H","year":"2018","unstructured":"Park H, Kim JW, Youk J, et al.. Serum free light chain difference and \u03b22 microglobulin levels are risk factors for thromboembolic events in patients with AL\u00a0amyloidosis. Clin Lymphoma Myeloma Leuk. 2018, 18:408-14. 10.1016\/j.clml.2018.03.005","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.02.078","article-title":"Predicting the unpredictable: how to score the risk of stroke in cardiac amyloidosis?","volume":"73","author":"Russo D","year":"2019","unstructured":"Russo D, Limite LR, Arcari L, Autore C, Musumeci MB. Predicting the unpredictable: how to score the risk of stroke in cardiac amyloidosis?. J Am Coll Cardiol. 2019, 73:2910-1. 10.1016\/j.jacc.2019.02.078","journal-title":"J Am Coll Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi S","year":"2015","unstructured":"Longhi S, Quarta CC, Milandri A, et al.. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid. 2015, 22:147-55. 10.3109\/13506129.2015.1028616","journal-title":"Amyloid"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi040","article-title":"Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques","volume":"26","author":"Modesto KM","year":"2005","unstructured":"Modesto KM, Dispenzieri A, Cauduro SA, et al.. Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J. 2005, 26:173-9. 10.1093\/eurheartj\/ehi040","journal-title":"Eur Heart J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2018.1430027","article-title":"Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis","volume":"25","author":"Henein MY","year":"2018","unstructured":"Henein MY, Suhr OB, Arvidsson S, Pilebro B, Westermark P, H\u00f6rnsten R, Lindqvist P. Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis. Amyloid. 2018, 25:46-53. 10.1080\/13506129.2018.1430027","journal-title":"Amyloid"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.10.037","article-title":"Relation of the CHA2DS2-VASc score to risk of thrombotic and embolic stroke in community-dwelling individuals without atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study)","volume":"123","author":"Koene RJ","year":"2019","unstructured":"Koene RJ, Alraies MC, Norby FL, et al.. Relation of the CHA2DS2-VASc score to risk of thrombotic and embolic stroke in community-dwelling individuals without atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study). Am J Cardiol. 2019, 123:402-8. 10.1016\/j.amjcard.2018.10.037","journal-title":"Am J Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.10.008","article-title":"CHA2DS2-VASc score: a predictor of thromboembolic events and mortality in patients with an implantable monitoring device without atrial fibrillation","volume":"92","author":"Parsons C","year":"2017","unstructured":"Parsons C, Patel SI, Cha S, et al.. CHA2DS2-VASc score: a predictor of thromboembolic events and mortality in patients with an implantable monitoring device without atrial fibrillation. Mayo Clin Proc. 2017, 92:360-9. 10.1016\/j.mayocp.2016.10.008","journal-title":"Mayo Clin Proc"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2020.100519","article-title":"Diagnosing cardiac amyloidosis in every-day practice: a practical guide for the cardiologist","volume":"28","author":"Papathanasiou M","year":"2020","unstructured":"Papathanasiou M, Carpinteiro A, Rischpler C, Hagenacker T, Rassaf T, Luedike P. Diagnosing cardiac amyloidosis in every-day practice: a practical guide for the cardiologist. Int J Cardiol Heart Vasc. 2020, 28:100519. 10.1016\/j.ijcha.2020.100519","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.08.002","article-title":"AL amyloidosis for the cardiologist and\u00a0oncologist: epidemiology, diagnosis, and management","volume":"1","author":"Witteles RM","year":"2019","unstructured":"Witteles RM, Liedtke M. AL amyloidosis for the cardiologist and\u00a0oncologist: epidemiology, diagnosis, and management. JACC CardioOncol. 2019, 1:117-30. 10.1016\/j.jaccao.2019.08.002","journal-title":"JACC CardioOncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar JA","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al.. 2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024, 149:e1-e156. 10.1161\/CIR.0000000000001193","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan E","year":"2019","unstructured":"Donnellan E, Elshazly MB, Vakamudi S, et al.. No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC Clin Electrophysiol. 2019, 5:1473-4. 10.1016\/j.jacep.2019.10.013","journal-title":"JACC Clin Electrophysiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson MM","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al.. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020, 142:e7-e22. 10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-830901","article-title":"Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition","volume":"132","author":"Wu S","year":"2018","unstructured":"Wu S, Chen X, Jin DY, Stafford DW, Pedersen LG, Tie JK. Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition. Blood. 2018, 132:647-57. 10.1182\/blood-2018-01-830901","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.28.12.2382","article-title":"Warfarin use among patients with atrial fibrillation","volume":"28","author":"Brass LM","year":"1997","unstructured":"Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke. 1997, 28:2382-9. 10.1161\/01.str.28.12.2382","journal-title":"Stroke"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/dj4010005","article-title":"New direct oral anticoagulants (DOAC) and their use today","volume":"4","author":"Schwarb H","year":"2016","unstructured":"Schwarb H, Tsakiris DA. New direct oral anticoagulants (DOAC) and their use today. Dent J (Basel). 2016, 4:5. 10.3390\/dj4010005","journal-title":"Dent J (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013, 369:2093-104. 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-51. 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.742428","article-title":"New oral anticoagulants vs. vitamin k antagonists among patients with cardiac amyloidosis: prognostic impact","volume":"8","author":"Cariou E","year":"2021","unstructured":"Cariou E, Sanchis K, Rguez K, et al.. New oral anticoagulants vs. vitamin k antagonists among patients with cardiac amyloidosis: prognostic impact. Front Cardiovasc Med. 2021, 8:742428. 10.3389\/fcvm.2021.742428","journal-title":"Front Cardiovasc Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.36628\/ijhf.2023.0031","article-title":"Direct oral anticoagulants in patients with cardiac amyloidosis: a systematic review and meta-analysis","volume":"6","author":"Lacy SC","year":"2024","unstructured":"Lacy SC, Kinno M, Joyce C, Yu MD. Direct oral anticoagulants in patients with cardiac amyloidosis: a systematic review and meta-analysis. Int J Heart Fail. 2024, 6:36-43. 10.36628\/ijhf.2023.0031","journal-title":"Int J Heart Fail"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3390%2Fbiomedicines10112888","article-title":"Arrhythmic burden in cardiac amyloidosis: what we know and what we do not","volume":"10","author":"Argir\u00f2 A","year":"2022","unstructured":"Argir\u00f2 A, Del Franco A, Mazzoni C, et al.. Arrhythmic burden in cardiac amyloidosis: what we know and what we do not. Biomedicines. 2022, 10:2888. 10.3390%2Fbiomedicines10112888","journal-title":"Biomedicines"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani LR","year":"2021","unstructured":"Mitrani LR, De Los Santos J, Driggin E, et al.. Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding. Amyloid. 2021, 28:30-4. 10.1080\/13506129.2020.1810010","journal-title":"Amyloid"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm AJ","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY, et al.. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010, 31:2369-429. 10.1093\/eurheartj\/ehq278","journal-title":"Eur Heart J"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2116","article-title":"Anticoagulation in atrial fibrillation","volume":"348","author":"Steinberg BA","year":"2014","unstructured":"Steinberg BA, Piccini JP. Anticoagulation in atrial fibrillation. BMJ. 2014, 348:g2116. 10.1136\/bmj.g2116","journal-title":"BMJ"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12602","article-title":"Stroke risk and atrial mechanical dysfunction in cardiac amyloidosis","volume":"7","author":"Ballantyne B","year":"2020","unstructured":"Ballantyne B, Manian U, Sheyin O, Davey R, De S. Stroke risk and atrial mechanical dysfunction in cardiac amyloidosis. ESC Heart Fail. 2020, 7:705-7. 10.1002\/ehf2.12602","journal-title":"ESC Heart Fail"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1177\/1753944716652787","article-title":"Apixaban to prevent stroke in patients with atrial fibrillation: a review","volume":"11","author":"Peterson BE","year":"2017","unstructured":"Peterson BE, Al-Khatib SM, Granger CB. Apixaban to prevent stroke in patients with atrial fibrillation: a review. Ther Adv Cardiovasc Dis. 2017, 11:91-104. 10.1177\/1753944716652787","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1177\/1076029615601492","article-title":"Direct oral anticoagulants for the management of thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes","volume":"22","author":"Amin A","year":"2016","unstructured":"Amin A, Marrs JC. Direct oral anticoagulants for the management of thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes. Clin Appl Thromb Hemost. 2016, 22:605-16. 10.1177\/1076029615601492","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1597758","article-title":"Initiating and managing patients with venous thromboembolism on anticoagulant drugs: a practical overview","volume":"34","author":"Kasthuri RS","year":"2017","unstructured":"Kasthuri RS, Moll S. Initiating and managing patients with venous thromboembolism on anticoagulant drugs: a practical overview. Semin Intervent Radiol. 2017, 34:3-10. 10.1055\/s-0036-1597758","journal-title":"Semin Intervent Radiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13283","article-title":"Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: a systematic review and meta-analysis","volume":"126","author":"Hellfritzsch M","year":"2020","unstructured":"Hellfritzsch M, Adelborg K, Damkier P, Paaske Johnsen S, Hallas J, Potteg\u00e5rd A, Grove EL. Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: a systematic review and meta-analysis. Basic Clin Pharmacol Toxicol. 2020, 126:21-31. 10.1111\/bcpt.13283","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2019.02.021","article-title":"Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study","volume":"73","author":"Anguita S\u00e1nchez M","year":"2020","unstructured":"Anguita S\u00e1nchez M, Bertomeu Mart\u00ednez V, Ruiz Ortiz M, et al.. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study. Rev Esp Cardiol (Engl Ed). 2020, 73:14-20. 10.1016\/j.rec.2019.02.021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1177\/2047487320920756","article-title":"Management of complications of cardiac amyloidosis: 10 questions and answers","volume":"28","author":"Aimo A","year":"2021","unstructured":"Aimo A, Rapezzi C, Vergaro G, Giannoni A, Spini V, Passino C, Emdin M. Management of complications of cardiac amyloidosis: 10 questions and answers. Eur J Prev Cardiol. 2021, 28:1000-5. 10.1177\/2047487320920756","journal-title":"Eur J Prev Cardiol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.06.018","article-title":"Influence of renal function on the pharmacokinetics, pharmacodynamics, efficacy, and safety of non-vitamin K antagonist oral anticoagulants","volume":"93","author":"Weir MR","year":"2018","unstructured":"Weir MR, Kreutz R. Influence of renal function on the pharmacokinetics, pharmacodynamics, efficacy, and safety of non-vitamin K antagonist oral anticoagulants. Mayo Clin Proc. 2018, 93:1503-19. 10.1016\/j.mayocp.2018.06.018","journal-title":"Mayo Clin Proc"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011409231","article-title":"Renal profiles of anticoagulants","volume":"52","author":"Harder S","year":"2012","unstructured":"Harder S. Renal profiles of anticoagulants. J Clin Pharmacol. 2012, 52:964-75. 10.1177\/0091270011409231","journal-title":"J Clin Pharmacol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3390\/ph9020017","article-title":"Non-steroidal anti-inflammatory drugs and aspirin therapy for the treatment of acute and recurrent idiopathic pericarditis","volume":"9","author":"Schwier N","year":"2016","unstructured":"Schwier N, Tran N. Non-steroidal anti-inflammatory drugs and aspirin therapy for the treatment of acute and recurrent idiopathic pericarditis. Pharmaceuticals (Basel). 2016, 9:17. 10.3390\/ph9020017","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2020.05.017","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: the growing need to look forward","volume":"6","author":"Kumar S","year":"2020","unstructured":"Kumar S, Bhaskaran A. Atrial fibrillation in transthyretin cardiac amyloidosis: the growing need to look forward. JACC Clin Electrophysiol. 2020, 6:1128-30. 10.1016\/j.jacep.2020.05.017","journal-title":"JACC Clin Electrophysiol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.20471\/acc.2019.58.04.22","article-title":"Inadequacy of vitamin K antagonist use in patients with atrial fibrillation - overview of everyday clinical practice at the Merkur University Hospital in Zagreb, Croatia","volume":"58","author":"Stipinovi\u0107 M","year":"2019","unstructured":"Stipinovi\u0107 M, Letilovi\u0107 T, Po\u010dani\u0107 D, A\u0107amovi\u0107 Stipinovi\u0107 B, Kurti\u0107 E, Serti\u0107 Z, Jerki\u0107 H. Inadequacy of vitamin K antagonist use in patients with atrial fibrillation - overview of everyday clinical practice at the Merkur University Hospital in Zagreb, Croatia. Acta Clin Croat. 2019, 58:744-50. 10.20471\/acc.2019.58.04.22","journal-title":"Acta Clin Croat"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101188","article-title":"Effectiveness and safety of oral anticoagulants in cardiac amyloidosis: lights and shadows","volume":"48","author":"Di Lisi D","year":"2023","unstructured":"Di Lisi D, Di Caccamo L, Damerino G, et al.. Effectiveness and safety of oral anticoagulants in cardiac amyloidosis: lights and shadows. Curr Probl Cardiol. 2023, 48:101188. 10.1016\/j.cpcardiol.2022.101188","journal-title":"Curr Probl Cardiol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient\u00a0with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson MM","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, et al.. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient\u00a0with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023, 81:1076-126. 10.1016\/j.jacc.2022.11.022","journal-title":"J Am Coll Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/257614-anticoagulation-in-atrial-fibrillation-associated-with-cardiac-amyloidosis-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T07:13:50Z","timestamp":1717398830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/257614-anticoagulation-in-atrial-fibrillation-associated-with-cardiac-amyloidosis-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":64,"URL":"https:\/\/doi.org\/10.7759\/cureus.61557","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}